FDA Grants Rare Pediatric Disease Designation to Sarizotan for Treating Rett Syndrome
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to sarizotan for the treatment of breathing difficulties in people with Rett syndrome. This designation provides priority review to investigational treatments that have the potential to provide clinically meaningful benefits for people with…